Boston Scientific Reports Strong Performance Data for SYNERGY Stent System, Shows Target Lesion Revascularization Remains Low
May 21, 2014 at 08:04 AM EDT
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the ...